drugset / Trial / NCT04975334

Opioid Antagonism in Hypogonadotropic Hypogonadism

NCT04975334

Phase 1 Completed 23 enrolled Massachusetts General Hospital
NaSingle-groupOpen-labelOther

Summary

The goal of this study is to evaluate the effects of opioid antagonists on the hypothalamic-pituitary-gonadal axis in subjects with hypogonadotropic hypogonadism (HH).

Timeline

Start
2025-06-18
Primary completion
2025-09-26
Completion
2025-09-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Naloxone Small molecule Intravenous